Influenza (Pandemic) Clinical Trial
Official title:
A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 2.
The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts of the study.
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02078674 -
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
|
Phase 1/Phase 2 | |
| Completed |
NCT00347529 -
Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu
|
Phase 1 | |
| Completed |
NCT01594320 -
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1
|
Phase 1 |